Lignocaine 50 mg/5 mL ampoules
Published 13 August 2017
Product
One batch: Batch A313 Expiry date: Nov 2017 ARTG Number AUST R 49296
Why it was recalled
Potential for incorrect product in package. Consumers and health professionals are advised that Pfizer, in consultation with the TGA, is undertaking a recall for product correction of one batch (Batch A313, expiry date Nov 2017) of Lignocaine 50 mg/5 mL ampoules because of the potential for the packaging to contain another product. Users with potentially affected products are asked to inspect their packs to ensure they contain the correct medicine. The recall for product correction was initiated after one NSW consumer being treated with a different Pfizer product, Heparin 5000 IU/5 mL injection 50 pack (Batch A473, expiry date Feb 2019), found the pack contained vials of Lignocaine. The consumer obtained the pack at a community pharmacy. Consumers and health professionals who identify a defective pack should follow the advice below.
Hazard
Heparin is used as a "blood-thinner" in people susceptible to blood-clotting and lignocaine is an anaesthetic. If a patient has an affected pack, there is a risk that they will not have adequate supply of their medicine and could take the incorrect medicine, which could have serious health consequences.
Source: Product Safety Australia. RecallMatch AU provides a screening summary and is independent of the ACCC.